T3 Companies’s IGC Pharma IGC Stock Holding History

T3 Companies’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.26K	Hold	20,000	–	–	0.01%	133
2025 Q4	$5.63K	Buy	+20,000	New	+$7.13K	0.01%	170

Other funds holding IGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lawood & Co Williamsport, Pennsylvania $148M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T3 Companies's IGC Position: Q1 2026 in Review

T3 Companies held its IGC Pharma (IGC) position steady in Q1 2026 at 20,000 shares worth $5.26K. The position accounts for 0.01% of the portfolio, ranked #133.

T3 Companies first reported a position in IGC in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.63K in Q4 2025. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.

T3 Companies held 20,000 shares of IGC Pharma worth $5.26K as of Q1 2026.
T3 Companies left its IGC Pharma share count unchanged in Q1 2026.
IGC Pharma made up 0.01% of T3 Companies's portfolio in Q1 2026, its #133 holding.
T3 Companies first reported a position in IGC Pharma in Q4 2025 and has held it in 2 quarters since.
T3 Companies's IGC Pharma position peaked at $5.63K in Q4 2025.
35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.

Based on T3 Companies's 13F filing for Q1 2026, filed 7 May 2026.